

<b>Reference:</b>	FOI.6693.21
<b>Subject:</b>	Dermatology
<b>Date of Request:</b>	16 August 2021

**Requested:**

- How many patients were treated in last 4 months by the Dermatology department with each of the following:
  - Abrocitinib
  - Acitretin
  - Alitretinoin
  - Azathioprine
  - Baricitinib
  - Ciclosporin
  - Dupilumab
  - Methotrexate
  - Mycophenolate mofetil
  - Pimecrolimus
  - Tacrolimus ointment
  - Tralokinumab
  - Upadacitinib
- For all the patients treated by the Dermatology department in the last 4 months with the products listed in the previous question, can you please tell us how many of these patients were Paediatric (age 17 and under) versus adult?

**Response:**

- The UHB provides, within the table below, the number of patients treated by the Dermatology Department with the listed medications, during the period 20 April to 20 August 2021.

Medication	Number
Abrocitinib	0
Acitretin	52
Alitretinoin	*
Azathioprine	12
Baricitinib	0
Ciclosporin	14
Dupilumab	32
Methotrexate	33
Mycophenolate mofetil	*
Pimecrolimus	*
Tacrolimus ointment	0
Tralokinumab	0
Upadacitinib	0

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients, due to the low numbers of cases (5 and under),

as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

2. Hywel Dda University Health Board is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of paediatric patients treated by the Dermatology Department that were prescribed the listed medications, the UHB would need to undertake a manual trawl of all patient records, to identify the information requested.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.